Cord blood stem cell-generated KIR+NK cells effectively target leukemia cell lines

Copyright © 2022 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved..

Acute lymphoid (ALL) and myeloid leukemia (AML) are known to be invasive and highly lethal hematological malignancies. Because current treatments are insufficient and have a variety of side effects, researchers are looking for new and more effective therapeutic methods. Interestingly, ongoing efforts to find the best approach to optimize NK cell anti-leukemia potential shed light on the successful treatment of cancer. Mature KIR+NK cells ability to remove HLA Class-I deficient cells has been exploited in cancer immunotherapy. Here, we generated KIR+NK cells from cord blood stem cells using IL-2 and IL-15 cytokines. Our finding underlined the importance of KIR expression in the cytotoxic function of NK cells. Taken together, this study presented an effective in vitro method for the expansion and differentiation of KIR+NK cells using cytokines without any feeder cells. Furthermore, the presented culture condition could be useful for the generation of mature and pure NK cells from limited numbers of CD34+ cord blood cells and might be used as a novel method to improve the current state of cancer therapy.

Medienart:

E-Artikel

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Zur Gesamtaufnahme - volume:84

Enthalten in:

Human immunology - 84(2023), 2 vom: 10. Feb., Seite 98-105

Sprache:

Englisch

Beteiligte Personen:

Dizaji Asl, Khadijeh [VerfasserIn]
Rafat, Ali [VerfasserIn]
Mazloumi, Zeinab [VerfasserIn]
Valipour, Behnaz [VerfasserIn]
Movassaghpour, Aliakbar [VerfasserIn]
Talebi, Mehdi [VerfasserIn]
Mahdavi, Majid [VerfasserIn]
Tayefi Nasrabadi, Hamid [VerfasserIn]
Nozad Charoudeh, Hojjatollah [VerfasserIn]

Links:

Volltext

Themen:

Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Cord Blood Stem Cells
Cytokines
Journal Article
Killer Cell Immunoglobulin-like Receptors (KIRs)
Natural Killer Cells
Receptors, KIR

Anmerkungen:

Date Completed 07.02.2023

Date Revised 07.02.2023

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1016/j.humimm.2022.10.010

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM349097976